Asacol Related Published Studies
Well-designed clinical trials related to Asacol (Mesalamine)
Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. [2008.10]
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. [2007.12]
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. [2007.01]
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. [2005.11]
Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. [2005.07]
Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. [2005.05.01]
Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. [2005.04]
Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. [2004.09]
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. [2004.09]
Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. [2004.05.15]
Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. [2003.07.24]
A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. [2003.05]
Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease. [2003.03]
The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. [2003.01]
Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. [2002.12]
A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. [2002.06]
Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine versus oral mesalamine. [2002.05]
Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. [2000.07]
Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. [2000.02]
Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. [1999.03]
A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. [1998.08.06]
Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. [1998.06]
Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. [1998.05]
Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. [1998.01]
A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. [1997.10]
A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. [1997.04]
A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. [1996.07]
Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. [1996.03]
Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. [1995.08]
Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. [1995.05]
Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. [1995.02]
Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. [1995.02]
A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. [1994.12]
Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. [1994.02]
Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). [1994.02]
Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. [1993.08]
Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. [1993.05]
Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID) [1993.02]
Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group. [1992.08]
Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. [1991.09.01]
Bioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazine. [1990.11]
Well-designed clinical trials possibly related to Asacol (Mesalamine)
Budesonide for induction of remission in Crohn's disease. [2008.07.16]
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. [2008.07]
Can 5-aminosalicylic acid suppository decrease the pain after rectal band ligation? [2008.06.14]
Interventions for treating lymphocytic colitis. [2008.04.16]
A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. [2008.01.07]
Successful Treatment of Steroid Refractory Active Ulcerative Colitis with Natural Interferon-beta - an Open Long-Term Trial. [2007.12]
Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. [2007.11.01]
Prevention of Complications and Symptomatic Recurrences in Diverticular Disease with Mesalazine: A 12-Month Follow-up. [2007.11]
Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin. [2007.10]
Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. [2007.09]
Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. [2007.07.01]
A clinical trial on absorption and N-acetylation of oral and rectal mesalazine. [2007.07]
Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease. [2007.06.15]
Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. [2007.06]
Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: A multicenter, randomized, double-blind study. [2007.04]
Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. [2007.03]
Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers. [2007.03]
Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. [2007.02]
Spotlight on VSL#3 Probiotic Mixture in Chronic Inflammatory Bowel Diseases. [2007]
Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment? [2007]
Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. [2006.12]
[Characterization of proteinuria in patients with ulcerative colitis and therapy with aminosalicylates] [2006.10.15]
Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. [2006.10.01]
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. [2006.06.01]
Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. [2006.05.15]
Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. [2006.04.01]
Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. [2006.04]
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. [2006.01]
Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: A double-blind, randomized, placebo-controlled study. [2005.12.07]
Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients. [2005.12.01]
A randomized trial of nicotine enemas for active ulcerative colitis. [2005.11]
Budesonide for induction of remission in Crohn's disease. [2005.10.19]
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. [2005.07]
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. [2005.06.16]
Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis. [2005.06.01]
Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. [2005.05.01]
A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. [2005.05]
Efficacy of mesalazine in the treatment of symptomatic diverticular disease. [2005.03]
A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. [2005.01.15]
Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial. [2004.12]
Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. [2004.11]
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. [2004.11]
Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. [2004.05]
Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. [2003.10]
Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study. [2003.07]
Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis. [2003.07]
Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. [2003.05.01]
Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. [2003.05.01]
Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. [2003.03]
Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. [2003.02.15]
Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. [2002.11]
Use of the 'nutriceutical', bovine colostrum, for the treatment of distal colitis: results from an initial study. [2002.11]
The effectiveness of budesonide therapy for Crohn's disease. [2002.08]
Infliximab improves quality of life in patients with Crohn's disease. [2002.07]
Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids (OPUS 1). [2002.03]
Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life. [2002.03]
Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. [2002.02]
Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. [2002.01]
Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. [2001.12]
Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. [2001.09.22]
|
